Curis Lifesciences Ltd
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]
- Market Cap ₹ 103 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 19.3
- Book Value ₹
- Dividend Yield %
- ROCE 41.1 %
- ROE 179 %
- Face Value ₹ 10.0
Pros
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 23.70 | 35.21 | 35.58 | |
| 20.12 | 31.95 | 27.14 | |
| Operating Profit | 3.58 | 3.26 | 8.44 |
| OPM % | 15.11% | 9.26% | 23.72% |
| 0.02 | 0.34 | 0.31 | |
| Interest | 1.62 | 1.33 | 0.85 |
| Depreciation | 0.75 | 0.73 | 0.68 |
| Profit before tax | 1.23 | 1.54 | 7.22 |
| Tax % | 59.35% | 20.13% | 25.90% |
| 0.49 | 1.23 | 5.36 | |
| EPS in Rs | |||
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 339% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 179% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 0.50 | 0.50 | 0.50 |
| Reserves | -1.40 | -0.18 | 5.18 |
| 17.62 | 16.19 | 17.09 | |
| 10.68 | 13.16 | 11.05 | |
| Total Liabilities | 27.40 | 29.67 | 33.82 |
| 12.33 | 12.20 | 11.59 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 |
| 15.06 | 17.46 | 22.22 | |
| Total Assets | 27.40 | 29.67 | 33.82 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 4.95 | 3.35 | 0.28 | |
| -0.37 | -0.55 | -0.06 | |
| -4.58 | -2.76 | 0.05 | |
| Net Cash Flow | -0.01 | 0.04 | 0.27 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 96.10 | 98.17 | 103.00 |
| Inventory Days | 208.46 | 114.92 | 273.44 |
| Days Payable | 359.58 | 262.67 | 228.28 |
| Cash Conversion Cycle | -55.01 | -49.58 | 148.16 |
| Working Capital Days | -16.02 | -20.84 | 30.88 |
| ROCE % | 17.21% | 41.09% |
Documents
Annual reports
No data available.
Business Profile[1]
Curis Lifesciences is a pharmaceutical company engaged in the production of a wide range of formulations across tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments.